anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain a synergistic effect of massage and slimming by preparing a solid salt by high pressure molding of a salt compounded with a crude drug- type effective ingredient and performing massage using this. CONSTITUTION:A salt massage tool A is prepd. by compounding a crude drug- type effective ingredient and performing compression molding of this under a loading pressure in the range of 1.5-3.0t/cm<2> by means of a pressing apparatus to prepare a solid salt l. The solid salt 1 is compounded with azulene 2 and the whole body is compression-molded into a column shape and each surface part being brought into contact with a body is made into a smooth face to take consideration not to damage the position for massage. In addition, ring-like holes 4 and ring-like recessed channels 3 are formed on the solid salt 1 and the ring-like holes 4 and the ring like recessed channels 3 are filled with soap 5. In another way, by utilizing the uneven parts formed on the surface without filling the soap, stimulus to the skin is enhanced. Using the above constituted salt massage tool A, as the salt, the crude drug and the soap 5 acts directly to the massage position, a synergistic effect can be obtd.
Participants assigned to the FFW group (i.e., FFW participants) will proceed through the pre-operative program provided by the center and will be given 4 weeks of 24 hr access to the FFW online intervention during data collection for this study. Intervention participants will: 1) watch original videos with vignettes performed by professional actors; 2) read and/or watch mini-lectures that teach skills for behavior change; 3) engage in self-reflection exercises, 4) play original interactive games related to vignettes and mini-lectures; 5) interact with other FFW users via chat room functions and; 6) watch funny narrated video clips about well-being and/or physical activity.
Teen participants (ages 13-17) will be randomly assigned to either the experimental group in which participants receive access to Happify Teens, a digital platform rooted in several therapeutic traditions that aims to improve wellbeing, or a waitlist control group. Both group conditions last 8 weeks. Participants assigned to the Happify Teens platform will have full access to the intervention, with featured tracks that focus on dealing with stress, worries and building skills for greater happiness. Participants assigned to the waitlist (control) condition will not have access to the Happify Teens platform for the full study period (12 weeks total). Participants in the waitlist control will receive access to Happify Teens after the full study period is complete (12 weeks). Perceived stress, rumination, and optimism will be assessed via self-report at baseline, end of the 8-week intervention, and at 1 month post intervention.
India is a large middle-income country and has surpassed China in overall population, comprising 20% of the global population (over 1.43 billion people). India is experiencing a major demographic shift in its aging population. Chronic diseases are common among older adults and can be persistent over the life course, lead to the onset of disability, and be costly. Among older adults in India, the existence of multiple comorbid chronic conditions (i.e., multimorbidity) is rapidly growing and represents a burgeoning public health burden. Prior research identified greater rates of multimorbidity (e.g., overweight/obesity diabetes, hypertension, cardiovascular disease, stroke, and malignancies) in minority populations in the United States (U.S.); however, limited studies have attempted to characterize multimorbidity among older adult sub-populations residing in India. To address this gap, we conducted a narrative review of studies on multimorbidity using the data from the Longitudinal Aging Study of India (LASI), the largest nationally representative longitudinal survey study of adults in India. Our definition of multimorbidity was the presence of more than two conditions in the same person. Our findings, based on 15 reviewed studies, aim to (1) characterize the definition and measurement of multimorbidity and to ascertain its prevalence in ethnically and culturally diverse sub-populations in India; (2) identify adverse outcomes associated with multimorbidity in the Indian adult population; and (3) identify gaps, opportunities, and future directions.
OBJECTIVE: This study aimed to evaluate the clinical application and efficacy of a super-low-positioned intestinal decompression tube in the treatment of intestinal obstruction.
METHODS: A total of 130 patients with postoperative small bowel obstruction were included in this study. The patients were divided into a super-low-positioned intestinal decompression group and a conventional intestinal decompression group. The clinical data, treatment outcomes, and complications were compared between the two groups.
RESULTS: The technical success rate of placing the super-low-positioned intestinal decompression tube was 100%, with no intraoperative complications. The patients in the super-low-positioned intestinal decompression group had a significantly shorter hospital stay (8.3 ± 5.2 vs 17.7 ± 13.3, P < 0.001) and a higher non-operative treatment success rate (83.6% vs 57.9%, P = 0.001) compared to the conventional intestinal decompression group. Multivariate logistic regression analysis showed that the placement of a super-low-positioned intestinal decompression tube was an independent protective factor for treatment outcomes (P = 0.001). The hospital stay was significantly shorter in the super-low-positioned intestinal decompression group compared to the conventional group in both successful non-operative treatment patients (6.9 ± 3.0 vs 11.2 ± 7.5, P < 0.001) and failed non-operative treatment patients (16.2 ± 7.4 vs 26.6 ± 14.4, P < 0.001). The super-low-positioned intestinal decompression tube effectively relieved the "Self-strangulation" phenomenon in patients with intestinal obstruction.
CONCLUSION: The super-low-positioned intestinal decompression tube is a safe and effective method for the treatment of intestinal obstruction, with better treatment outcomes and shorter hospital stays compared to conventional intestinal decompression. Further prospective studies are needed to validate these findings.
Due to deep location and for being adjacent to neurovascular structures, petroclival meningiomas (PCMs) are generally considered to be associated with a high rate of recurrence and cranial nerve deficits.1 This video presents a 49-year-old female patient reporting right trigeminal neuralgia for more than 1 year. The incidence of this symptom with PCMs is about 5%.2 According to the classification system proposed by Kawase et al.3 and Ichimura et al.,4 this is a tentorium type PCM. A modified anterior petrosectomy approach was adopted based on the tumor size and its origin. The case presentation, surgical technique, postoperative outcome are reviewed. The treatments to the intraoperative trochlear nerve injury and temporal bridging vein occlusion are displayed (Video 1). The patient gave verbal consent for participating in the procedure and surgical video.
While big data has emerged as a global concern for information technology, attention is focused on what a public institution and companies will create which value through the big data collected so far. Therefore, a big data management system for a livestock disease outbreak information service constitutes development stages as follows. Firstly, the present invention develops a big data collector module for livestock disease outbreak information to collect disease outbreak data provided from public/private institutions as various sources in web portals, an SNS, and intranet inside public institutions in real time. Secondly, the present invention develops a big data real-time storing manager module for livestock disease outbreak information to store and manage the collected big data through a Hadoop distributed file system (HDFS), and store and manage the big data in a relational DB by performing real-time distributed parallel processing through a map reduce framework. Thirdly, the present invention develops a big data analyzing and visualizing processor module to analyze data for each subject by using real-time data mining technology from the stored livestock disease outbreak data and predict classification, grouping, and disease outbreak progress. Finally, the present invention develops a livestock disease outbreak information analyzing services system to effectively provide a service for disease outbreak statistics, disease outbreak policies, and disease outbreak prediction for strengthen national ability to respond to the livestock disease outbreak from the analyzed livestock disease outbreak information data.
Concurrent direct and indirect inguinal, femoral, and obturator hernias are rare. This case report describes a rare case treated using the laparoscopic approach. A 68-year-old female patient presented with a moving left inguinal lump and pain. Physical examination and abdominal computed tomography scan revealed the coexistence of a left inguinal hernia or Nuck canal hydrocele and a left femoral hernia. The patient underwent laparoscopic transabdominal preperitoneal repair, and all four orifices were covered with one mesh. The patient was discharged on the second postoperative day without any complications. The concurrent presence of four hernias on the same side is rare and has not been previously reported. The laparoscopic approach is useful in such cases because it allows visualization of multiple hernia orifices from the intra-abdominal cavity.
After anesthesia and surgical procedures, an ESP block will be applied under ultrasonography guidance from the midline 3 cm lateral from the T5 level. After cleaning the area with povidone-iodine before the block, the T5 transverse protrusion will be determined using a linear ultrasound probe. Local anesthetic will be applied between the transverse process and the erector spinae muscle with the help of an insulated needle designed for peripheral block procedures. The location of the needle will be confirmed by hydrodissection with physiological saline without local anesthesia. Once the location of the needle is confirmed, a mixture of 20 ml of 0.25% bupivacaine will be applied.
A method  and  composition  for the  inhibition of growth of Salmonella is provided.  The effective compos-ition of the invention is a class of fructo-oligosac-charides which inhibit the growth of Salmonella.   More particularly,  the  fructo-oligosaccharides  are  sucrose molecules having from 1 to 8 fructose residues.   This class  of  sugars  is  exemplified  by  "Neosugar"  which includes  1-kestose,  nystose,  and  1-fructofuranosyl-nystose.  The present method includes contacting Salmon-ella  with  the  effective  composition and can  include feeding it to a domestic food animal.  The present com-position includes the effective component and nutritive feed material.
Participants take 500 mg of Curcumin phytosome twice daily for one week. Two blood draws are taken on both the first and last days of the week. One blood draw is done fasted just before consumption of one supplement dose, and one blood draw is done after consumption of one supplement dose.
The initial percutaneous transhepatic puncture of the bile duct is performed by ultrasound guidance with a Chiba-needle (0.7 mm). After injection of a radiopaque contrast media into the bile duct system, the malignant extrahepatic bile duct stenosis can be visualized by fluoroscopic guidance (digital remote-controlled fluoroscopy device). Then a 0.018 inch guide wire is introduced and proceeded beyond the tumor stenosis into the duodenum. Next, the Chiba needle is exchanged by a 5 F catheter and the 0.018 inch guide wire is exchanged by a 0.035 inch guide wire. After dilatation of the hepatic access route with bougies up to 12 F, a self-expandable metal stent is introduced. The placement of the metal stent is controlled by endoscopic luminal guidance (gastroscope or duodenoscope).
1429096 Antibiotic 60-6 SHIONOGI & CO Ltd 24 April 1974 [25 April 1973] 17941/74 Heading C2A An antibiotic, designated 60-6, which antibiotic is a colourless amphoteric powder which shows no definite M.Pt. but progressively decomposes over 140 C.; which contains C, H, N and O in the following proportions by wt.: which has an optical rotation of [α]<SP>23À0</SP> D  + 19À8  3À5 (C=0À172% in dimethylformamide); which has a M.Wt. of 1600 and a neutralization equivalent of 1517; which forms aspartic acid, threonine, serine, valine, alloisoleucine, tryptophan, γ-hydroxylysine, ammonia and a variety of fatty acids of 12-16 carbon atoms upon acid hydrolysis; which has ultraviolet absorption bands (in methanol) at 275, 282 and 290À5 mÁ; which has a solubility as defined; which exhibits positive ninhydrin and Dragendorff colour reactions; which exhibits behaviour on t.l.c. as specified; and which has an infra-red absorption spectrum as shown in the accompanying drawing. The antibiotic may be prepared by cultivating a suitable strain of Bacillus cereus in an aqueous nutrient medium under aerobic conditions. A suitable strain is Bacillus cereus No. 60-6, ATCC No. 21929. Preferred cultivation conditions are a temperature of 20-37 C., submerged aerobic conditions, a nutrient medium pH of 7-8, and the optional presence of a buffering agent and an anti-foaming agent. The cultivation proceeds preferably for 20-100 hours, after which the antibiotic may be isolated by filtering the broth and extracting both cells and filtrate with a suitable solvent. There may be prepared, from the antibiotic, salts such as an acid addition salt, an ammonium salt or a pharmaceutically acceptable salt. The antibiotic may be formed into a pharmaceutical or disinfectant composition by admixture with a suitable diluent, carrier or excipient.
Pneumococci are bacteria which can cause serious and potentially life threatening illnesses like meningitis and blood poisoning. There are \~90 strains, some are more dangerous than others in the severity of the disease they cause. Around half of all children carry pneumococci at the back of their nose without any ill effect. Pneumococcal vaccines (PCV) have been given in the national immunisation schedule since 2006. Vaccines protect individuals by making antibodies to be made in the blood and these vaccines help to clear the pneumococci from the nose, which helps control disease in the population by stopping their onward transmission when children cough and sneeze. This clearing effect is specific to the strains that are included in the vaccine. The first vaccines used included seven (PCV7) strains and the one used currently includes 13 (PCV13).

This group has conducted three previous carriage studies, and this will be the fourth. The first was before any vaccine was used, the second just after PCV7 was introduced and the third after the UK moved to using PCV13. These carriage studies allow assessment of how the strains in the nose change over time, in that by clearing some strains away which other strains take up those niches in their place both in children and in their close/household contacts. This helps to inform the best use of the vaccines available and for future vaccine development and which strains would be useful to include.

All families registered at participating surgeries, with a child aged 1-5 years, will be invited to take part. The study involves a single nasopharyngeal swab and a saliva swab from the child and as many other household members as are happy to participate. Participants may be seen at their GP surgery or in the home if more mutually convenient
Mast cells serve as crucial effector cells within the innate immune system and are predominantly localized in the skin, airways, gastrointestinal tract, urinary and reproductive tracts, as well as in the brain. Under physiological conditions, brain-resident mast cells secrete a diverse array of neuro-regulatory mediators to actively participate in neuroprotection. Meanwhile, as the primary source of molecules causing brain inflammation, mast cells also function as the "first responders" in brain injury. They interact with neuroglial cells and neurons to facilitate the release of numerous inflammatory mediators, proteases, and reactive oxygen species. This process initiates and amplifies immune-inflammatory responses in the brain, thereby contributing to the regulation of neuroinflammation and blood-brain barrier permeability. This article provides a comprehensive overview of the potential mechanisms through which mast cells in the brain may modulate neuroprotection and their pathological implications in various neurological disorders. It is our contention that the inhibition of mast cell activation in brain disorders could represent a novel avenue for therapeutic breakthroughs.
Participants received a single dose of 300 milligrams (mg) etokimab administered on Day 1 by intravenous (IV) infusion over 1 hour. After completing the Day 1 assessments, all participants were followed up for 18 weeks.
This protocol will attempt to follow all of the procedures of the actual AMCT protocol except no thrust will be delivered. Self-care only participants successfully completing the 6 month assessment will be given the option for RIST or AMCT for one month.
FIELD: medicine. SUBSTANCE: method involves cutting out skin flap immediately in the surgical access area. Subcutaneous fat is carefully removed and perforation holes are made all over the whole flap surface. Herniotomy is carried out in usual way with wound edges separated to healthy aponeurosis. Abdominal wall aponeurosis is sutured with parietal peritoneum. The prepared skin flap is laid with dermal surface turned towards the aponeurosis. The fixation is carried out above the former defect area in stretched state. Injections are done all around the aponeurosis at 10-12 points with alloplant solution 0.5 cm apart from aponeurosis edge. 0.5 is injected into each point. EFFECT: prevented suture eruption; reduced risk of disease recurrence.
This includes toxicity arising from accidental intravascular injection of ORABLOC discussed in Section 5.1, as well as that related to higher systemic concentrations of local anesthetics or epinephrine [see Warnings and Precautions (5.3)]. Systemic absorption of local anesthetics including ORABLOC can produce effects on the central nervous and cardiovascular systems.

At blood concentrations achieved with therapeutic doses of ORABLOC, changes in cardiac conduction, excitability, refractoriness, contractility, and peripheral vascular resistance are minimal. However, toxic blood concentrations of ORABLOC can depress cardiac conduction and excitability, which may lead to atrioventricular block, ventricular arrhythmias, and cardiac arrest, possibly resulting in fatalities. In addition, myocardial contractility is depressed and peripheral vasodilatation occurs, leading to decreased cardiac output and arterial blood pressure. ORABLOC should also be used with caution in patients with heart block as well as those with impaired cardiovascular function since they may be less able to compensate for functional changes associated with the prolongation of A-V conduction produced by these drugs.

Restlessness, anxiety, tinnitus, dizziness, blurred vision, tremors, depression, or drowsiness may be early warning signs of central nervous system toxicity.

Careful and constant monitoring of cardiovascular and respiratory (adequacy of ventilation) vital signs and the patient’s state of consciousness should be performed after each local anesthetic injection of ORABLOC. Repeated doses of ORABLOC may cause significant increases in blood levels because of possible accumulation of the drug or its metabolites. The lowest dosage that results in effective anesthesia should be used to decrease the risk of high plasma levels and serious adverse effects. Tolerance to elevated blood levels varies with the status of the patient. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use. Precautions for epinephrine administration, discussed in Section 5.3 should be observed.

Debilitated patients, elderly patients, acutely ill patients, and pediatric patients should be given reduced doses commensurate with their age and physical condition [see Dosage and Administration (2.1, 2.3)]. No studies have been performed in patients with liver dysfunction, and caution should be used in patients with severe hepatic disease.
This was a prospective, multicenter study in subjects with chronic kidney disease. The study was designed to address hemoglobin stability after drug conversion to epoetin alfa in subjects previously receiving darbepoetin alfa therapy.

The study was to enroll approximately 180 subjects with chronic kidney disease. Eligible subjects were those with chronic kidney disease who were receiving darbepoetin alfa every two, three, or four weeks for a period of 3 months or more and who had a stable hemoglobin (Hb) level at study entry of 12 g/dL (plus or minus 1 g/dL (11-13 g/dL). Subjects receiving darbepoetin alfa every 2, 3 or 4 weeks were switched over to epoetin alfa which they received at the same dosing frequency ( every 2, 3 or 4 weeks) upon study entry and throughout the 24 week study period. Clinical safety was assessed for the occurrence and severity of adverse events. Blood tests (Complete Blood Count, platelets, reticulocyte count, iron, were assessed at pre-determined intervals throughout the study. Vital signs (e.g. Blood pressure) were checked at each visit. Subjects received epoetin alfa at the same dosing frequency that they had previously received darbepoetin alfa. Subjects received 20,000 Units (U) epoetin alfa subcutaneously (SC) every two weeks; 30,000 U epoetin alfa SC every 3 weeks; or 40,000 U epoetin alfa SC every 4 weeks.
Split-thickness skin grafting (STSG) is one of the most commonly used techniques in reconstructive plastic surgery and dermatology. Skin grafts are being used to cover skin defects caused by multiple etiologies. Traditionally, patients are immobilized in bed or in wheelchair for up to five days after surgery. Long immobilization decreases patients overall ability to function and increases the length of the stay in hospital. Negative pressure wound therapy (NPWT) have been used successfully in treatment of acute, chronic and diabetic ulcers. It is proposed that NPWT increases capillary blood flow, decreases bacterial contamination, seroma formation and swelling. Using NPWT on split-thickness skin grafts after burns is well documented. It increases skin graft take ratio and speeds up healing. Aim of this study is to compare NPWT to traditional treatment after STSG for any indication in patients aged 18 to 99. This is a two-arm, multicenter, randomized prospective trial with 160 patients.
Laparoscopic +/- open appendicectomy, with antibiotics at induction and 3 further doses of intravenous antibiotics. Co-amoxiclav, or cefuroxime and metronidazole if previous rash-allergy to penicillin.
The present application relates to devices, systems and methods for delivering therapeutic agents into the stomach wall. Embodiments of the present application provide swallowable devices, formulations, and methods for delivering drugs and other Therapeutic Agents (TA) within the GI tract and specifically to the sinus wall (AW). Particular embodiments provide a Swallowable Device (SD), such as a capsule, for delivering drugs or other TAs to an AW. The SD may house a pressure sensitive component or assembly that triggers release and insertion of a therapeutic agent formulation (TAP) comprising at least one TA into the AW in response to external pressure, such as pressure applied to a swallowable capsule or other SD due to sinus shrinkage. Particular embodiments of the SD may be shaped such that it self-aligns within the sinus to orient properly before insertion of the TAP into the AW. Embodiments of the present application are particularly useful for oral delivery of drugs or other TAs that degrade in the GI tract and require parenteral injection.